[1]Kaplan SA. Re: impact of 5α-reductase inhibitor and α-blocker therapy for benign prostatic hyperplasia on prostate cancer incidence and mortality[J]. J Urol, 2020, 203(5): 856-857.
[2]Alshalalfa M, Liu Y, Wyatt AW, et al. Characterization of transcriptomic signature of primary prostate cancer analogous to prostatic small cell neuroendocrine carcinoma[J]. Int J Cancer, 2019, 145(12): 3453-3461.
[3]Langston ME, Sfanos KS, Khan S, et al. Why do epidemiologic studies find an inverse association between intraprostatic inflammation and prostate cancer: a possible role for colliding bias?[J]. Cancer Epidemiol Biomarkers Prev, 2021, 30(2): 255-259.
[4]Yang L, Li XM, Zhang MN, et al. Nomogram models for distinguishing intraductal carcinoma of the prostate from prostatic acinar adenocarcinoma based on multiparametric magnetic resonance imaging[J]. Korean J Radiol, 2023, 24(7): 668-680.
[5]Lai SS, Zheng SL. Diagnostic value of radiomics based on fat-suppressed T2-weighted imaging magnetic resonance imaging for pelvic metastatic lymph nodes of prostate cancer[J]. Journal of China Medical University, 2021, 50(3): 230-234. (in Chinese)
赖树盛,郑石磊. 基于磁共振T2WI-FS的影像组学对前列腺癌盆腔淋巴结转移的诊断价值[J]. 中国医科大学学报,2021,50(3): 230-234.
[6]Bailey C, Bourne RM, Siow B, et al. VERDICT MRI validation in fresh and fixed prostate specimens using patient-specific moulds for histological and MR alignment[J]. NMR Biomed, 2019, 32(5): e4073.
[7]Huang H, Chen S, Li W, et al. Periprostatic fat thickness on MRI is an independent predictor of time to castration-resistant prostate cancer in Chinese patients with newly diagnosed prostate cancer treated with androgen deprivation therapy[J]. Clin Genitourin Cancer, 2019, 17(5): e1036-e1047.
[8]Chen XP, Wang JP, Zhao JZ. Surgery[M]. 9th ed. Beijing: People’s Medical Publishing House, 2018: 572-574. (in Chinese)
陈孝平,汪建平,赵继宗. 外科学[M]. 第9版. 北京:人民卫生出版社,2018: 572-574.
[9]Nakajima K, Mizokami A, Matsuyama H, et al. Prognosis of patients with prostate cancer and bone metastasis from the Japanese Prostatic Cancer Registry of Standard Hormonal and Chemotherapy Using Bone Scan Index cohort study[J]. Int J Urol, 2021, 28(9): 955-963.
[10]Pan B, Aherne NJ, Shakespeare TP, et al. Bone health assessment with dual energy X-ray absorptiometry in men with high-risk prostate carcinoma commencing adjuvant androgen deprivation therapy[J]. Rep Pract Oncol Radiother, 2022, 27(4): 677-683.
[11]Xu X, Fallah M, Tian Y, et al. Risk of invasive prostate cancer and prostate cancer death in relatives of patients with prostatic borderline or in situ neoplasia: a nationwide cohort study[J]. Cancer, 2020, 126(19): 4371-4378.
[12]Yang LY, Jia ZH, Pan D, et al. Correlation study of CT and MRI findings, biological factor expression, and lymph node metastasis in aggressive prostate cancer[J]. Progress in Modern Biomedical, 2022, 22(9): 1779-1784. (in Chinese)
杨留洋,贾招辉,潘冬,等. 侵袭性前列腺癌的CT、MRI表现与生物因子表达及淋巴结转移的相关性研究[J]. 现代生物医学进展,2022,22(9): 1779-1784.
[13]Sanguineti G, Bertini L, Faiella A, et al. Response on DCE-MRI predicts outcome of salvage radiotherapy for local recurrence after radical prostatectomy[J]. Tumori, 2021, 107(1): 55-63.
[14]Stanzione A, Cuocolo R, Cocozza S, et al. Detection of extraprostatic extension of cancer on biparametric MRI combining texture analysis and machine learning: preliminary results[J]. Acad Radiol, 2019, 26(10): 1338-1344.
[15]Ranasinghe WKB, Troncoso P, Surasi DS, et al. Defining diagnostic criteria for prostatic ductal adenocarcinoma at multiparametric MRI[J]. Radiology, 2022, 303(1): 110-118.
[16]Christophe C, Montagne S, Bourrelier S, et al. Prostate cancer local staging using biparametric MRI: assessment and comparison with multiparametric MRI[J]. Eur J Radiol, 2020, 40(132): 109350.
[17]Zhang YK, Guo L, Liu YQ, et al. Changes in semi-quantitative parameters of DCE-MRI in bone metastases of prostate cancer[J]. Radiology in Practice, 2025, 40(7): 903-907. (in Chinese)
张亚坤,郭立,刘宇奇,等. 前列腺癌骨转移灶的DCE-MRI半定量参数变化[J]. 放射学实践, 2025, 40(7): 903-907.
[18]He L, Liao B, Che NY, et al. Value of multiphase dynamic contrast-enhanced magnetic resonance imaging parameters combined with serum prostate-specific antigen levels in predicting postoperative prognosis of patients with prostate cancer[J]. Chinese Journal of Sexual Science, 2024, 33(4): 21-25. (in Chinese)
何亮,廖波,车能雨,等. 多期动态增强磁共振成像参数联合血清前列腺特异性抗原水平预测前列腺癌患者术后预后的价值分析[J]. 中国性科学, 2024, 33(4): 21-25.
[19]Zhang Y, Li Z, Gao C, et al. Preoperative histogram parameters of dynamic contrast-enhanced MRI as a potential imaging biomarker for assessing the expression of Ki-67 in prostate cancer[J]. Cancer Med, 2021, 10(13): 4240-4249.
[20]Daniel M, Polanec SH, Wengert G, et al. Intra- and inter-observer variability in dependence of T1-time correction for common dynamic contrast enhanced MRI parameters in prostate cancer patients[J]. Eur J Radiol, 2029, 39(116): 27-33.
[21]Liu L, Zhou SK, Zhang GY, et al. Comparison of the diagnostic value of 18F-PSMA PET/CT and mpMRI for pelvic lymph node metastasis in prostate cancer[J]. Chinese Journal of Urology, 2022, 43(1): 40-45. (in Chinese)
刘磊,周术奎,张桂银,等. 18F-PSMA PET/CT与mpMRI对前列腺癌盆腔淋巴结转移诊断价值的比较[J]. 中华泌尿外科杂志,2022,43(1): 40-45.
[22]Kim TH, Woo S, Han S, et al. The diagnostic performance of the length of tumor capsular contact on MRI for detecting prostate cancer extraprostatic extension: a systematic review and meta-analysis[J]. Korean J Radiol, 2020, 21(6): 684-694.
[23]Shen QY, Gu HM. Prediction of clinically significant prostate cancer based on multiparametric MRI radiomics[J]. Chinese Journal of CT and MRI, 2024, 22(1): 120-123. (in Chinese)
沈茜樱,顾红梅. 基于多参数磁共振放射组学预测临床显著性前列腺癌[J]. 中国CT和MRI杂志,2024,22(1): 120-123.
[24]Li J, Zou CX, Pan NN, et al. Prediction of endocrine therapy response in prostate cancer using DCE-MRI pharmacokinetic parameters histogram[J]. Magnetic Resonance Imaging, 2025, 16(4): 70-80. (in Chinese)
李静,邹彩霞,潘妮妮,等. DCE-MRI药代动力学参数直方图预测前列腺癌内分泌治疗反应的研究[J]. 磁共振成像,2025,16(4): 70-80.